Alternative Recommendation Table

Intervention MildModerateSevereCriticalCertainty of evidenceDate of Recommendation
• Symptomatic (any acute COVID-19 related symptoms)
• AND respiratory rate <24/min
• WITHOUT pneumonia or hypoxia
• Pneumonia (clinical or radiological) OR hypoxia (SpO2 <94% in adults with no underlying lung disease)
• AND respiratory rate ≤30/min
• AND SpO2 ≥90% on room air
Pneumonia with ANY ONE of the following:

• RR >30/min
• severe respiratory distress
• SpO2 <90% on room air
• NO invasive or non-invasive respiratory support needed
• Requirement for high-level respiratory support: NIV or HFNO or IMV
• OR ARDS (PaO2/FiO2 ratio of <300)
• OR sepsis
• OR shock
AntiviralAzithromycin Not recommended
Not recommended Not recommended Not recommended
⨁⨁⨁⨁
HIGH
27/09/2021
Ivermectin Not recommended Not recommended Not recommended Not recommended
⨁⨁⨁⨁
HIGH
15/05//2021
Hydroxychloroquine / Chloroquine Not recommended Not recommended Not recommended Not recommended
⨁⨁⨁◯
MODERATE
04//02/2022
Favipiravir Not recommended Not recommended Not recommended Not recommended
⨁◯◯◯
VERY LOW
19/07/2021
Remdesivir Not recommended Recommended % Recommended % Recommended %
⨁⨁⨁◯
MODERATE
16/06/2022
Interferons Not recommended Not recommended Not recommended Not recommended
⨁⨁⨁◯
MODERATE
27/10/2021
Molnupiravir Recommended *
Recommended *
Not recommended Not recommended
⨁◯◯◯
VERY LOW

16/02/2022
Anti- inflammatories Tocilizumab/ Sarilumab Not recommended Not recommended Recommended *
Recommended *
⨁⨁⨁◯
MODERATE
24/05/2021
Baricitinib Not recommended Recommended π Recommended π Recommended π
⨁⨁⨁◯
MODERATE
17/09/2021
Inhaled corticosteroids Recommended $ Not recommended Not recommended Not recommended
⨁⨁◯◯
LOW
21/06/2021
Systemic corticosteroids Not recommended Not recommended Recommended @ Recommended @
⨁◯◯◯
VERY LOW
15/07/2021
Colchicine Not recommended Not recommended Not recommended Not recommended
⨁⨁◯◯
LOW
03/09/2021
Itolizumab Not recommended Not recommended Not recommended Not recommended
⨁◯◯◯
VERY LOW
22/11/2021
ThromboprophylaxisTherapeutic dose Vs Nontherapeutic dose of thromboprophylaxis Recommended α Recommended β Recommended β Recommended α
⨁⨁⨁◯
MODERATE
08/08//2022
AntibodyConvalescent Plasma Not recommended Not recommended Not recommended Not recommended
⨁⨁⨁⨁
HIGH

27/10/2021
Casirivimab-Imdevimab Recommended £ Recommended £ Not recommended Not recommended
⨁⨁⨁⨁
HIGH
11/08/2021
Respiratory TherapiesNIV Vs HFNO Recommended Recommended Recommended Recommended
⨁◯◯◯
VERY LOW

27/07/2021
Oxygen Saturation Targets Recommended Recommended Recommended Recommended
⨁◯◯◯
VERY LOW
12/02/2022
Other Supportive ManagementProne Positioning Not recommended
Recommended Recommended Recommended
⨁◯◯◯
VERY LOW

05/11/2021
* :- Only in patients with mild to moderate covid-19 with risk factors for developing severe disease.
# :- Tocilizumab 8mg/kg, maximum 800mg as a single dose
$ :- for symptomatic relief.
@ :- 6 mg of Dexamethasone or equivalent per day IV or Oral till normalization of Oxygen saturation or max 10 days.
% :- Remdesivir 200 mg IV OD on the first day followed by 100 mg IV OD from Day 2-5, to be given with in 5 days of symptom onset
α :-Enoxaparin 40 mg SC OD
β :- Enoxaparin 40 mg OD to 1 mg/Kg BD SC
π :- 4 mg once daily for 14 days or until discharge
£ :- Only for patients with non-omicron variant with a risk factor for severe illness, and no detectable covid-19 antibodies present in their body. Casirivimab 600 mg + Imdevimab 600 mg as a single infusion within 10 days of symptom onset.
Ω :- Target SPO2 at 94-98%.

Strong against recommendation
Conditional against recommendation
Conditional for recommendation
Strong for recommendation